Esteve Pharmaceuticals SA - Company Profile
Powered by 
All the data and insights you need on Esteve Pharmaceuticals SA in one report.
$295
- Save hours of research time and resources with
our up-to-date Esteve Pharmaceuticals SA Strategy Report
- Understand Esteve Pharmaceuticals SA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Esteve Pharmaceuticals SA (Esteve) researches, develops, and markets prescription and generic pharmaceuticals. The company's product portfolio includes prescription drugs, over the counter (OTC) pharmaceuticals, and generic drugs. It offers drugs for the central nervous system, infection, respiratory, cardiovascular, cancer, primary care, and other therapeutic areas. Esteve also provides customized contract manufacturing services of active pharmaceutical ingredients (APIs) and advanced intermediates for the global pharmaceutical industry. The company markets its products to pharmaceutical companies, healthcare facilities and other customers through licensing agreements and distributors. It operates subsidiaries and production centers in Europe, the Americas, Africa, Oceania, and Asia. Esteve is headquartered in Barcelona, Spain.
Headquarters
Spain
Address
109, 4th Floor, Passeig de la Zona Franca, Barcelona, Barcelona , 08038
Website
www.esteve.com
Telephone
34 93 4466000
No of Employees
1,824
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$696.4M
Esteve Pharmaceuticals SA premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Prescription | Contract Manufacturing Services | Thiotepa Riemser |
| Vision Care | Retinest | |
| Integral Care | Velyntra | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In April, the company signed an agreement to acquire Hra Pharma Rare Diseases from Perrigo. |
| 2023 | New Products/Services | In July, the company introduced INBRIJA 33 mg in Spain. |
| 2023 | Plans/Strategy | In May, the company announced its plans to sell a 26% stake to Lubea. |
Competitor Comparison
| Key Parameters | Esteve Pharmaceuticals SA | Almirall SA | Covex SA | J Uriach Y Compania SA | Laboratorios Juventus SA |
|---|---|---|---|---|---|
| Headquarters | Spain | Spain | Spain | Spain | Spain |
| City | Barcelona | Barcelona | Madrid | Barcelona | Madrid |
| State/Province | Barcelona | - | Madrid | Barcelona | Madrid |
| No. of Employees | 1,824 | 1,904 | - | - | - |
| Entity Type | Private | Public | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Albert Esteve | Chairman | Executive Board | 2018 | 65 |
| Staffan Schuberg | Chief Executive Officer; Director | Executive Board | 2018 | 55 |
| Daniel Girona | Director; Chief Legal Officer | Executive Board | 2024 | 52 |
| Roser Gomila | Chief Financial Officer | Senior Management | 2023 | 54 |
| M. Angels Valls | Public Affairs Officer; Chief Communications Officer | Senior Management | 2019 | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer